Apogee’s $350M offering; BiomX merges with Adaptive Phage

Plus, news about Telios Phar­ma and Celldex Ther­a­peu­tics:

An­oth­er day, an­oth­er pub­lic of­fer­ing: Apogee Ther­a­peu­tics is aim­ing to raise $350 mil­lion in a stock sale an­nounced the same day that it shared Phase I da­ta for its atopic der­mati­tis treat­ment in healthy vol­un­teers that hints at po­ten­tial­ly longer dos­ing in­ter­vals. — Jaimy Lee

Bio­mX merges with Adap­tive Phage Ther­a­peu­tics: The com­bined phage ther­a­py biotech will have two Phase II as­sets: BX004 for chron­ic pul­monary in­fec­tions in cys­tic fi­bro­sis, and BX211 for di­a­bet­ic foot os­teomyelitis. Bio­mX al­so se­cured a $50 mil­lion pri­vate place­ment to ad­vance the pro­grams through clin­i­cal read­outs in 2025. — Ay­isha Shar­ma

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.